News and Events
Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.
Featured News Item
New pathobiology studies look to accelerate RECOVER’s progress
The next phase of RECOVER’s pathobiology studies will focus on discoveries that can more immediately inform efforts to diagnose, prevent, and treat Long COVID.
Feature
58 Results
58 Results
RECOVER-TLC to discuss status of Long COVID clinical trials at annual workshop
Registration is open for the third annual RECOVER-TLC Workshop, where researchers, clinicians, people living with Long COVID, and advocates will discuss the latest clinical trial updates and the future of Long COVID research.
Feature
RECOVER Research Update: September 2026
RECOVER researchers continue to publish findings that could help scientists, doctors, patients, and caregivers navigate the complexities of Long COVID.
Research Update
RECOVER-VITAL clinical trial finds no benefit of extended duration of PAXLOVID for Long COVID
RECOVER researchers conducted a clinical trial to test whether PAXLOVID, an antiviral drug, could reduce Long COVID symptoms when taken for 15 or 25 days. The study enrolled 959 adults with Long COVID at 69 sites across the US.
News Release
Biosamples from RECOVER clinical trials offer expanded opportunities for Long COVID research
Biosamples collected during RECOVER clinical trials can provide valuable information about how people’s bodies respond to treatment. Researchers who receive funding through a new research opportunity can now access these samples.
Feature
RECOVER launches new funding opportunity for pathobiology research
NIH invites investigators to apply for a new research opportunity, which funds pathobiology studies. Applicants can request use of data and biosamples from RECOVER observational studies and, for the first time, RECOVER clinical trials.
Announcement
R3 Seminar Recap: RECOVER clinical trial results and the pursuit of Long COVID treatments
During the July 14 RECOVER Research Review (R3) Seminar, panelists Craig Reist, PhD; David S. Knopman, MD; and Pam R. Taub, MD, shared findings from the RECOVER Clinical Trials (RECOVER-CT) program, the initiative's first wave of clinical trials. The trials focused on Long COVID symptoms related to thinking and memory, as well as the autonomic nervous system, which controls body functions like heart rate and blood pressure. RECOVER-CT Engagement Lead, Renee Leverty, MA, BSN, and Patient Representative Marta Cerda, JD, also explained how patient, caregiver, and community input shaped the trial design process.
R3 Seminar Recap
RECOVER at mid-year: 2026 progress and what’s ahead
In 2026 so far, RECOVER has published new research findings across nearly all its different studies and will soon be enrolling participants for the next phases of the adult observational study and clinical trials.
Feature
RECOVER to share clinical trial updates at July 2026 webinars
During 2 webinars, RECOVER researchers and leaders will discuss its clinical trial programs—RECOVER-CT and RECOVER-TLC, including clinical trial results to date and what it means to take part in a Long COVID clinical trial.
Feature